Press releases
- Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
- Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
- Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
- Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference
- Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates
- Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress
- Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
- Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
More ▼
Key statistics
As of last trade, Adicet Bio Inc (1IJA:MUN) traded at 1.26, 19.89% above the 52 week low of 1.05 set on Jul 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.26 |
---|---|
High | 1.26 |
Low | 1.26 |
Bid | 1.33 |
Offer | 1.37 |
Previous close | 1.20 |
Average volume | 279.78 |
---|---|
Shares outstanding | 82.17m |
Free float | 80.86m |
P/E (TTM) | -- |
Market cap | 118.33m USD |
EPS (TTM) | -2.95 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 07:12 BST.
More ▼